Clinical Trials
20 trialsNCT07609940 2026-05-27
POPLIN
Regeneron Pharmaceuticals
Phase 4 Not yet recruiting
NCT03434730 2026-05-26
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT07570173 2026-05-26
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT04524871 2026-05-22
MORPHEUS-LIVER
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05169515 2026-05-18
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT07594067 2026-05-18
TCR1188-ABC Cells in KRAS-mutated Cancers
University of Pennsylvania
Phase 1 Not yet recruiting
NCT07589634 2026-05-15
TRI Pro
Janssen Research & Development, LLC
Phase 2 Not yet recruiting
NCT05646836 2026-05-14
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Active not recruiting
NCT03337698 2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Terminated
NCT06934044 2026-05-11
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1 Recruiting
NCT03564340 2026-05-08
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05846789 2026-05-08
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Indiana University
Phase 2 Recruiting
NCT05171647 2026-05-07
SUNMO
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05535244 2026-05-07
CAMMA 2
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05091424 2026-05-04
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 1 Recruiting
NCT05533775 2026-05-04
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05583617 2026-05-04
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05927571 2026-05-04
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Recruiting
NCT06084936 2026-05-04
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT06624085 2026-05-04
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting